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Antiamyloid clinical trials for Alzheimer’s disease (AD)
have been unsuccessful to date [1]. The failure of such trials
was partially caused by the fact that participants enrolled insuch trials present clinically with AD but lack amyloidosis
[2]. Furthermore, most such trials have been conducted rela-
tively late in the disease process and targeting treatment to
earlier presymptomatic or prodromal stages of the disease
might have more success [3]. As a consequence, it has
L. Shi et al. / Alzheimer’s & Dementia 15 (2019) 1478-14881480increasingly common to conduct clinical trials in preclinical
or prodromal disease where AD pathology is confirmed us-
ing biomarkers [2,4]. Currently, the best characterized
methods for measuring amyloid pathology are positron
emission tomography (PET) imaging measures of brain
amyloid deposition and cerebrospinal fluid (CSF)
measurement of amyloid b (Ab) levels [5]. However, these
measures are challenging because of invasiveness, cost,
and restricted availability [6,7].
Blood-based biomarkers have therefore been investigated
as a less-invasive and potentially cost-effective option for
early detection and monitoring of AD pathology. An
increasing number of studies [8–12], including those by
ourselves [13–19], have found that a range of proteins in
plasma can reflect neocortical Ab burden and hence might
act as biomarkers. Recent studies have added to these by
demonstrating that measures of Ab in blood can predict
brain amyloid with high accuracy [20–22], further
indicating that blood proteins can be effective biomarkers
for predicting brain pathology.
The failure of antiamyloid clinical trials also provoked
some to question the amyloid cascade hypothesis [23–25].
Broadly speaking, the amyloid cascade hypothesis states
that over time, an imbalance in Ab production and/or
clearance leads to gradual accumulation and aggregation
of the peptide in the brain, initiating a neurodegenerative
cascade that involves not only amyloid deposition but also
inflammation, tau pathology, neuronal dysfunction, and
loss [26,27]. Despite some reservations regarding this
hypothesis prompted by the failure of clinical trials,
amyloid still remains a central part of our understanding of
the pathophysiology of the disease. Nonetheless, assessing
the relationship between amyloid and other AD
pathologies has become increasingly important.
With this in mind, we embarked on the study reported
here, with two main objectives; first to identify a plasma mo-
lecular signature of amyloid pathology for potential use as a
biomarker for preclinical or prodromal detection of disease
and second to investigate the causal relationship between
amyloid and other AD pathologies. We report here a repli-
cating signature of disease reflecting brain amyloid load
and other features of AD, including tau pathology, in blood.
Then using Mendelian randomization (MR) [28], an
approach more often used in genetic studies, we find a causal
relationship between amyloid and tau while such reverse
relationship was not found.2. Methods
2.1. Participants: EMIF-AD Multimodal Biomarker
Discovery study
The EMIF-ADMultimodal Biomarker Discovery (MBD)
study is part of the European Medical Information Frame-
work for Alzheimer’s disease (EMIF-AD; http://www.
emif.eu); a public-private precompetitive cross Europeanprogram seeking to make data, and in these case samples, re-
useable for secondary studies of neurodegeneration. The
design of the EMIF-ADMBD study has been described pre-
viously [29]. Briefly, 1221 participants meeting specified
and previously reported inclusion criteria were identified
from 11 preexisting European cohorts (“parent cohorts”) us-
ing the EMIF catalog (https://emif-catalogue.eu) and associ-
ated tools. Each parent cohort was approved by local
medical ethics committees. As reported previously [29], a
critical criterion for inclusion was that a measure of brain
amyloid load was available, using either CSFAb or amyloid
PET scan. The classification of amyloid burden (high/low) in
the EMIF-AD MBD cohort has been described previously
[29]. Furthermore, Ab measurements were combined into
a continuous variable using z-scoring, using the mean and
standard deviation of the control subjects as a reference [29].
In addition to the primary outcome variable of amyloid
load, another five markers in CSF were measured including
total tau (t-tau), phosphorylated tau (p-tau), neurofilament
light chain (NFL), neurogranin, and YKL-40 [29]. The
levels of t-tau and p-tau in CSF were measured locally,
and the local cutoff point was used to determine their status
(high/low). Consequently, the p-tau and t-tau values were Z-
scored with controls within each data set as a reference. The
other three CSF markers (NFL, neurogranin, and YKL-40)
were measured in a central laboratory (Gothenburg Univer-
sity, Sweden), and their status (high/low) was determined by
the median value of each marker within the whole data set.
In addition, the following AD-related phenotypes were
also measured: magnetic resonance imaging values of hip-
pocampal volume; clinical assessments including baseline
diagnosis, baseline Mini–Mental State Examination
(MMSE) score, and mild cognitive impairment (MCI) con-
version; and finally, apolipoprotein E (APOE) and genome-
wide single nucleotide polymorphism (SNP) genotyping
[29]. SNP assays were conducted using the “Global
Screening Array” (Illumina, Inc.) using standard procedures
from 250 ng of DNA extracted from whole blood [30]. Raw
data processing and initial quality control (QC) were per-
formed in GenomeStudio (v2.0.2) using GenTrain (v3.0)
as clustering algorithm generating genotypes for 645,896
SNPs. Postprocessing was performed in PLINK (v1.9) using
standard QC thresholds (i.e., sample genotyping efficiency
. 95%, SNP genotyping efficiency . 98%, departures
from Hardy Weinberg equilibrium at P value , .000005,
and a minor allele frequency [MAF] of, 0.01). Eventually,
this left 490,717 SNPs for analysis. Genotypes for recon-
struction of the APOE ε2/3/4 haplotypes were either gener-
ated on the Global Screening Array (rs7412) or by manual
genotyping (rs429358) as described previously [31]. We
classified individuals as APOE ε4 carriers or noncarriers ac-
cording to their genotype status at rs429358 (C-allele5 ε4).
The 1221 subjects selected for the EMIF-AD MBD
cohort included 492 healthy controls (HCs), 527 MCI, and
202 AD participants. Among these participants, we included
in the study all those that had plasma samples available (total
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groups, with each group of samples being processed inde-
pendently. Group 1 was used as a discovery group and
included 150 HCs (29.1%), 188 MCI (36.4%), and 178
AD (34.5%). Group 2 was used for validation and included
161 HCs (44.1%), 198 MCI (54.2%), and 6 AD (1.6%).
Furthermore, we sought to maintain amyloid balance in con-
trols and MCI individuals given that the objective is to iden-
tify biomarkers of amyloid pathology in preclinical stage. As
a result, in this combined group of samples from people in
the HC and MCI categories (total n 5 697), there were
338 with and 359 without amyloid pathology.
2.2. SOMAscan assay
We measured proteins in plasma using the SOMAscan
assay platform (SomaLogic Inc.). SOMAscan is an
aptamer-based assay allowing for the simultaneous measure-
ment and quantification of, in the version used here, 4001
proteins. The assay uses chemically modified nucleotides
to transform a protein signal into a nucleotide signal that
can be quantified using relative fluorescence on microarrays
[32]. As noted previously, groups of samples were measured
independently. Forty subjects were tested in both batches to
normalize the data across assay runs.
2.3. Statistical analysis
All statistical analyses were completed using R (version
3.3.2). The Mann-Whitney U test was used to compare par-
ticipants’ characteristics between high- and low-amyloid cat-
egories in both groups. The association between proteins and
amyloid Z-scorewas calculated by partial Spearman correla-
tion, adjusting for five covariates including age, sex, APOE
ε4 status, study of origin, and number of blood freeze-thaw
cycles. False discovery rate correction was used to correct
P values for multiple comparisons. Proteins that were differ-
entially expressed at a significance level of P , .05 were
further nominated for pathway analysis using the Metascape
software (http://metascape.org/gp/index.html#/main/step1).
Briefly, differentially expressed proteins were inputted as
“protein list” and all 4001 proteins measured by SOMAscan
assay were used as “background.” This enrichment analysis
was performed on the KEGG database.
2.4. Machine learning
Machine learningwas used to identify optimalmultivariate
signatures, including both proteins and demographic data (age
and APOE ε4) as input features, to differentiate between high
and low Ab status in group 1. First, the effects of study and
blood freeze-thaw cycle on proteins were removed by linear
regression and the residuals were used for analysis. Subse-
quently, Lasso was used to select the “n” top input features
that best differentiated high from low Ab. Support vector ma-
chine classifierswere then built using from1 to 100 features to
predict the outcome under 10-fold cross-validation. Thosefeatures that produced best performance were selected from
group 1. To verify replication, the optimal classifier was
then validated in the second and combined cohorts for distin-
guishing Ab status and other AD endophenotypes.2.5. Mendelian randomization
MR was used to investigate the causal relationship be-
tween amyloid and tau pathology. MR uses genetic variants
as an instrument when they are robustly associated with a
risk factor (exposure), with the fundamental assumption
that they are associated with the studied outcome through
that exposure. As genetic variants cannot be altered and
are static throughout an individual’s lifetime, reverse causa-
tion can be excluded, rendering MR a powerful tool to
examine causality between the exposure and outcome [28].
To explore the causal relationship between amyloid and tau
(both t-tau and p-tau), we first performed a systematic review
of the literature to search SNPs that were significantly associ-
ated with amyloid but not with tau or p-tau. Overall, 78 SNPs
were found to be significantly associated with abnormal amy-
loid pathology measured by PET scan, CSF amyloid, or post-
mortem measurement (Supplementary Table 1). Six SNPs
were excluded including 3 which were also associated with
t-tau and p-tau and 3 which were within 1 Mb of APOE
(i.e., APOC1 and TOMM40), given that APOE is strongly
associated with both amyloid and tau. Of the remaining
SNPs, 6 were not measured using the assay we used, leaving
66 SNPs for further analysis (Supplementary Table 1). The as-
sociation of these 66 SNPs with the Z-score of amyloid, t-tau,
and p-tau was calculated using PLINK (v1.7). Finally, based
on the association, we used four MR approaches, including
MR Egger linear regression, weighted median, inverse-
variance weighted (IVW), and simple median [33], to investi-
gate the causal relationship between amyloid and tau (both
t-tau and p-tau). Each MR method is based on different as-
sumptions. The Egger method is sensitive to SNP pleiotropy
and allows the estimation of underlying bias by allowing a
non-zero estimate for the intercept of the calculated ratio of
b values [34]. The weighted median method uses a median
of the individual causal estimate per SNP, which is calculated
from the ratio estimates of outcome’s regression coefficient
divided by exposure [35]. The IVWmethod uses the same ra-
tio estimates but incorporates IVWs into the final summary es-
timate [36]. Comparing estimates from all the methods shows
the robustness of the overall analysis. Furthermore, to deter-
mine if there was any single SNP driving the relationship,
we performed a leave-one-out analysis where the MR is per-
formed removing a different SNP in each iteration [37].
A similar approach was performed to investigate the
causal relationship between t-tau and amyloid. Using the
same approach, we identified 21 SNPs that were signifi-
cantly associated with the abnormal CSF t-tau level but
not with amyloid (Supplementary Table 2). After checking
the effect allele, eighteen SNPs passed QC and were used
for MR analysis (Supplementary Table 2). The causal
Table 1
Demographics of the study population
Characteristics
Group 1 (n 5 516) Group 2 (n 5 365)
High Ab (n 5 369) Low Ab (n 5 147) P value High Ab (n 5 134) Low Ab (n 5 231) P value
Ab Z-score 21.39 6 0.50 0.49 6 0.57 ,.001* 21.22 6 0.40 0.52 6 0.67 ,.001*
Age (yrs) 70.0 6 8.2 68.3 6 8.4 .04* 70.0 6 8.3 64.9 6 8.1 ,.001*
Female sex, N (%) 210 (57) 62 (42) .002* 70 (52) 139 (60) .14
Male sex, N (%) 159 (43) 85 (58) .002* 64 (48) 92 (40) .14
APOE ε41, N (%) 244 (66) 43 (29) ,.001* 76 (57) 53 (23) ,.001*
APOE ε42, N (%) 125 (34) 104 (71) ,.001* 58 (43) 178 (77) ,.001*
MMSE 24.1 6 4.6 27.0 6 3.2 ,.001* 26.9 6 2.7 28.2 6 1.8 ,.001*
NOTE. Percentage of cases is shown in brackets for female and male sex, as well as APOE ε4 carriers and noncarriers in each amyloid b (Ab) category.
P values compare each demographic across the high Ab and low Ab groups. Group 1 containing 516 participants was used for discovery, and group 2 of
365 participants for validation.
Abbreviations: APOE, apolipoprotein E; MMSE, Mini–Mental State Examination.
*P , .05.
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because few SNPs were found to be strongly associated
with p-tau. Therefore, this approach was underpowered for
making causal inferences.3. Results
3.1. Subject demographics
The EMIF-MBD cohort comprises 1221 subjects of
which 881 had samples available for this study. As described
in the Methods section, these were divided into two groups
for discovery and validation purposes. Table 1 shows the
characteristics of the participants from two groups split by
amyloid status (high/low). For both groups, the participants
with high amyloid were older (P 5 .04 in group 1, P, .001
in group 2), the MMSE was lower (P , .001 in group 1,
P , .001 in group 2), and the prevalence of APOE ε4
carriers was higher (P , .001 in group 1, P , .001 in group
2). A significant difference in sex was found in group 1
(P 5 .002), whereas there was no difference in group 2
(P 5 .14).3.2. Proteins significantly associated with amyloid
Z-score in both groups
In this study, we sought to find plasma biomarkers related
to amyloid pathology independent of diagnosis and so com-
bined samples from study participants across the AD diag-
nostic spectrum (HC, MCI, and AD) and used measures of
amyloid pathology as the principle outcome measure.
Combining samples in this way reflects the operational
need for a biomarker predicting brain amyloid pathology.
Recent experience suggests that up to 20% of people with
a diagnosis of AD in clinical trials had little or no brain am-
yloid pathology, demonstrating that clinical classification is
an inadequate predictor of brain pathology. Moreover, a
biomarker of brain pathology in all three states—HC,
MCI, and AD—would have value. In HC, a marker of brain
amyloid would help to identify preclinical AD, in MCI, toidentify prodromal AD, and in AD itself, to add to the accu-
racy of diagnosis.
Overall, 3676 and 3916 proteins passed QC measures in
group 1 and group 2, respectively. Using partial correlation
to analyze the association between proteins and amyloid
Z-score, we found that in group 1, 301 proteins reached sta-
tistical significance (P , .05) and 5 of them reached false
discovery rate (q, 0.1) (Supplementary Table 3), corrected
for multiple comparisons. In group 2, 536 proteins reached
statistical significance (P, .05) while none passed false dis-
covery rate. Fig. 1A and B shows volcano plots of proteins
from both groups with cutoff P 5 .05.
We then merged the lists of differentially expressed pro-
teins obtained from both groups finding a total of 786 pro-
teins associated with high versus low amyloid. This
number of dysregulated proteins was significantly higher
than that obtained by chance alone (P , .001). We then
used the Metascape software, performed on the KEGG data-
base, to assess the biological significance of these dysregu-
lated proteins. Pathway analysis of the 786 differentially
expressed proteins revealed 10 significantly enriched path-
ways: arginine biosynthesis (P5 .003), inflammatory medi-
ator regulation of TRP channels (P 5 .007),
glycerophospholipid metabolism, (P 5 .010), citrate cycle
(P 5 .012), Notch signaling (P 5 .016), RNA degradation
(P5 .023), type II diabetes mellitus (P5 .038), peroxisome
(P5 .038), fatty acid degradation (P5 .041), and NOD-like
receptor signaling (P 5 .043) pathways.3.3. Multiprotein classifier of amyloid normal/abnormal
status and other AD endophenotypes
Having demonstrated that plasma proteins are signifi-
cantly altered in samples from people with abnormal Ab
levels, we then sought to find a minimal signal from these
plasma data that might act as a biomarker indicative of brain
amyloid pathology. To do this we performed machine
learning with 10-fold cross-validation in group 1 to identify
the optimal multivariate signatures that differentiated be-
tween high- and low-Ab individuals. We first used
Fig. 1. Correlation of plasma proteins with amyloid Z-score by partial Spearman correlation. (A and B) Volcano plot of proteins obtained from group 1 and
group 2, respectively.
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ε4 as input features to predict amyloid burden. Results
showed that a combination of age and APOE ε4 achieved
the highest predictive value AUC of 0.70. Then, we added
all measured proteins to these demographic variables and
we found that a panel of 46 features achieved the highest pre-
dictive value AUC of 0.78. The input features automatically
selected by the classifier were age, APOE ε4, and 44 proteins
(Supplementary Table 4). The AUC in training and testing
sets for different number of input features is shown in
Supplementary Fig. 1. We then investigated the performance
of this classifier on differentiating amyloid status in the sec-
ond and independent group, maintaining the parameters ob-
tained from group 1. The results showed that the same panel
achieved an AUC of 0.68, demonstrating good replication
(Fig. 2A).
We further investigated the performance of the same
panel to predict other AD endophenotypes in the combined
cohort (combining groups one and two), including discrim-Fig. 2. (A) AUC of the 46 signatures to differentiate amyloid status in group 1 an
notypes in the combined cohort. Abbreviations: AUC, area under the curve; HC, h
phorylated tau; MMSE, Mini–Mental State Examination; NFL, neurofilament liginating AD from HC and AD from MCI, differentiating sta-
tus of t-tau, p-tau, MCI conversion, baseline MMSE score,
hippocampal volume, and other three CSF biomarkers
including NFL, neurogranin, and YKL-40. As shown in
Fig. 2B, the panel predicted most of these AD phenotypes
with an AUC of .0.6, except for CSF NFL, neurogranin,
and YKL-40. The sample size and AUC of each AD pheno-
type is shown in Supplementary Table 5.3.4. Causal relationship between amyloid and tau
pathology
We then sought to use these data to address the critically
important question of causality in relation to AD patholog-
ical features. To investigate the causal relationship between
amyloid and tau, we first identified SNPs associated with
amyloid pathology from systematic review of the literature.
We found 72 SNPs (Supplementary Table 1) significantly
associated with abnormal amyloid but not with taud group 2. (B) AUC of the 46 signatures to differentiate other AD endophe-
ealthy control; MCI, mild cognitive impairment; t-tau, total tau; p-tau, phos-
ht chain.
Table 2
MR estimates of the causal effect of amyloid on t-tau and p-tau as well as the
causal effect of t-tau on amyloid
Study type Methods b se 95% CI P value
Amyloid
SNPs with t-tau
MR Egger 0.85 0.15 0.54 to 1.15 ,.001
Weighted
median
0.73 0.22 0.31 to 1.16 ,.001
IVW 0.86 0.11 0.65 to 1.08 ,.001
Simple
median
0.81 0.50 20.17 to 1.80 .110
Amyloid
SNPs with p-tau
MR Egger 0.73 0.17 0.39 to 1.06 ,.001
Weighted
median
0.62 0.23 0.17 to 1.06 .006
IVW 0.86 0.12 0.62 to 1.10 ,.001
Simple
median
1.31 0.52 0.29 to 2.33 .014
t-tau
SNPs with
amyloid
MR Egger 20.45 0.36 21.15 to 0.26 .23
Weighted
median
20.31 0.29 20.87 to 0.25 .27
IVW 20.02 0.20 20.42 to 0.38 .93
Simple
median
20.20 2.05 24.22 to 3.81 .92
Abbreviations: b, b coefficient; CI, confidence interval; IVW, inverse-
variance weighted; MR, Mendelian randomization; t-tau, total tau; p-tau,
phosphorylated tau; SNP, single nucleotide polymorphism.
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this study (Supplementary Table 1) and hence available for
MR analysis. Results showed that amyloid was associated
with a moderate alteration in t-tau when using three MR ap-
proaches including the Egger method (b 5 0.85, se 5 0.15,
95% CI [0.54, 1.15], P, .001), the IVW method (b5 0.86,
standard error of the effect size [se] 5 0.11, 95% CI [0.65,
1.08], P , .001), and weighted median method (b 5 0.73,
se 5 0.22, 95% CI [0.31, 1.16], P , .001), though not
from simple median method (b 5 0.81, se 5 0.50, 95% CI
[-0.17, 1.80], P 5 .11; Table 2, Supplementary Fig. 2).
Altered amyloid was also associated with p-tau in all four
MR approaches (Table 2, Supplementary Fig. 2). Results
from leave-one-out analysis demonstrated that no single
SNP was driving the majority of the association signal be-
tween amyloid and either t-tau or p-tau (Supplementary
Fig. 3). In addition, we explored the causal relationship be-
tween amyloid and other three CSF markers including NFL,
neurogranin, and YKL-40; no significant association be-
tween amyloid and these three markers was found
(Supplementary Table 6).
We then reversed the direction of analysis and investi-
gated whether there was a causal relationship between t-
tau and amyloid. Twenty-one SNPs (Supplementary
Table 2) were found to be significantly associated with the
abnormal CSF t-tau level from systematic review, among
which eighteen SNPs (Supplementary Table 2) passed QC
and were used for MR analysis. Results showed no causal
relationship between t-tau and amyloid from any of the
four MR approaches (Table 2). We also investigated the
causal relationship between t-tau and other three CSF
markers (NFL, neurogranin, and YKL-40). No causal rela-
tionship between t-tau and NFL was found, whereas suchrelationship was found between t-tau and neurogranin as
well as between t-tau and YKL-40 (Supplementary Table 6).4. Discussion
In this study, we used the SOMAscan assay to measure
4001 proteins in plasma in two groups of subjects from the
EMIF-AD MBD study. Using machine learning, we identi-
fied a panel of 44 proteins that, along with age and APOE
ε4, predicted measures of central amyloid with good perfor-
mance in both the discovery group (AUC 5 0.78) and the
replication group (AUC 5 0.68). The same panel also pre-
dicted other AD phenotypes, including CSF t-tau, CSF
p-tau, MCI conversion, baseline MMSE score, and hippo-
campal volume. Moreover, a causal relationship between
amyloid and t-tau and with p-tau was confirmed using a
MR approach, whereas evidence for the reverse relationship
between t-tau and amyloid was not found.
These results are in concordance with one of our previous
studies [18], in which we used the same SOMAscan assay to
measure plasma proteins in 58 cognitively healthy men. In
this previous study, 667 proteins were significantly associ-
ated with CSF amyloid measurement, and of these 167 pro-
teins (25%) overlapped with the differentially expressed
proteins obtained in the present study. Furthermore, the
number of overlapping proteins was significantly higher
than expected from chance alone (P 5 .01), confirming
that the SOMAscan assay may be a useful and powerful
screening tool for identifying plasma proteins reflecting am-
yloid deposition in early, even preclinical, phases of disease
and across the clinical AD spectrum as in the present study.
Pathway analysis of the 786 differentially expressed pro-
teins revealed 10 significantly enriched pathways. When
comparing these enriched pathways with AlzPathway, a
comprehensive map of AD signaling and related pathways
[38,39], we found two pathways common to both; Notch
signaling and type II diabetes mellitus. This finding is
interesting given that multiple lines of evidence have
previously shown that Notch signaling and type II diabetes
mellitus are associated with AD [40–43]. Our results add
weight to this finding and indicate that proteins involved in
these two pathways could be treatment targets of AD.
From the discovery phase of the present study, a panel of
46 features achieved a high AUC in discriminating high from
low brain amyloid (Fig. 2A). Age and APOE ε4 contributed
to the model, as in previous studies seeking biomarkers
indicative of brain amyloid; unsurprisingly given that both
age and APOE genotype are highly associated with amyloid
pathology [44–48]. Despite this, the protein signature
consisting of 44 proteins achieved a greater discrimination
performance in the discovery group than age and APOE ε4
(0.78 vs. 0.70). In this study, as the sample collection was
deliberately selected to overrepresent high amyloid
individuals, the proportion of APOE ε4 carriers in the
sample collection is higher than in the general population
(47.2% vs. 10-20% [49]). In the real world of clinical trials
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fying people with likely AD pathology as most people in the
early stages of disease are APOE ε4 negative. Because of
this, an algorithm that relies on APOE genotype to identify
people for inclusion in clinical trials is of limited value,
and hence, the identification of additional markers, such as
we report here, is even more valuable than a modest increase
in AUC over a predictor that includes APOE would suggest.
This study is the largest we are aware of to report a plasma
biomarker indicative of AD pathology both in terms of the
number of proteins assayed and in samples size. Recently,
Nakamura et al. (2018) [20] and Ovod et al. (2017) [21] re-
ported methods to measure plasma Ab directly, and Ashton
et al. (2019) [50] used high-resolution mass spectrometry to
identify plasma proteins that correlate with altered central
amyloid. In all three cases, these assays achieve higher mea-
sures of accuracy than we report. However, our study is
considerably larger and conducted in a mixed cohort derived
frommultiple different sources. By virtue of this size and the
likely heterogeneity of the sample characteristics, it is
possible that the results we report here are likely towithstand
the rigors of application in the real-world situations of multi-
centre, multinational complex clinical trials. Moreover, the
analytical platform we use here is clinic-ready and relatively
low cost. Finally, using the panel we describe could have sig-
nificant economic benefits. Based on the performance of our
panel (AUC 5 0.78, sensitivity 5 0.84, specificity 5 0.54),
we obtain a likelihood ratio of 1.82, suggesting that the panel
could improve approximately 15% in amyloid detection [51]
relative to current practice. Given that screen failure rates for
amyloid positive recruitment to clinical trials is approxi-
mately 70%, then to recruit 100 individuals there is a need
to enroll 333 participants with a cost of approximately
$1.7 million ($5000 per scan). A 15% improvement as we
demonstrate would reduce the number needed to screen
from 333 to 222, with a cost saving of $0.55 million per
100 participants of a clinical trial. Therefore, as trials typi-
cally seek to recruit large numbers of participants, especially
in late phase, we believe that despite the moderate improve-
ment of AUC, these 44 proteins obtained from our large sam-
ple size study are strong candidates and worthy of further
investigation.
The National Biomarker Development Alliance proposes
6 steps for any biomarker development (nbdabiomarkers.
org/) including early discovery, translatable discovery, assay
development, assay performance, biomarker quantification,
and biomarker validation. Here, we have discovered and
replicated 44 nominated biomarkers, the subsequent phase
of research will be “translatable discovery,” indicating that
we need to replicate these 44 proteins in even larger indepen-
dent cohorts to further minimize overfitting and to obtain a
smaller panel of proteins. One of the advantages of the plat-
form that we used here, SOMAscan, is that it is a high-
quality assay platform already in increasingly wide research
use and appropriate for clinical implementation. In the short
to medium term, the results we present here might be used inprescreening processes to recruit people to clinical trials
where screening includes determination of amyloid status
by CSF or PET markers. Currently, the very high screen fail-
ure rate at this stage slows clinical development and adds
substantially to the cost of clinical trials while also exposing
large numbers of potential participants to relatively invasive
tests. Our data suggest that this prescreen failure when
seeking people with brain pathology could be reduced using
a simple blood assay. In future years, an assay such as this
could be used as part of a clinical workup directing at risk
individuals to specific testing—such as by CSF measures
or using PET imaging—before therapeutic intervention.
In addition to predicting amyloid status, the 44 proteins
along with age and APOE ε4 could also predict other AD en-
dophenotypes including discriminating AD from HC and
AD from MCI, differentiating status of t-tau, p-tau, MCI
conversion, baseline MMSE score, and hippocampal vol-
ume. These findings are in concordance with some recent
studies [52,53] and further demonstrate the association of
amyloid pathology with other pathologies of AD.
Moreover, these findings are potentially useful in clinical
trial settings especially as increasing number of clinical
trials are directed at tau-related targets [1]. The biomarker
panel that we report here could potentially be used in very
large numbers of people to identify those likely to have
both amyloid and tau pathology, even in preclinical phase.
Despite more than two decades of study, the mechanism of
ADpathology is still disputedwith serial trials failure provok-
ing some to question the amyloid cascade hypothesis. Broadly
speaking, this states that the generation of Ab leads, through a
series of largely unknown steps, to tau pathology and hence
neuronal dysfunction and dementia [26,27]. Using the data
generated here we confirmed the relationship between
amyloid and tau pathology using two approaches. First, the
proteins selected from amyloid prediction also predict tau
pathology (CSF t-tau and p-tau). Second, we used MR, a
method more commonly used in genetic studies to go
beyond association to causality, finding that higher amyloid
levels drive a moderate increase in both t-tau and p-tau but
that the reverse (t-tau driving amyloid pathology) is not true.
Our results confirm the crucial role of amyloid in driving tau
pathology marking the onset of preclinical AD, and
consistent with previous findings [53–55].
Interestingly, no such association was found between amy-
loid and other three CSF biomarkers (NFL, neurogranin, and
YKL-40), either from using proteins to discriminate their
levels or fromMR analysis. This suggests that these three bio-
markers (NFL, neurogranin, andYKL-40) play different roles
inAD independent of, or at least remote from, amyloid pathol-
ogy.Although their role is not understoodcompletely, changes
in NFL are thought to reflect axonal damage [56], changes in
neurogranin to reflect synaptic dysfunction [57], and changes
in YKL-40 to provide a measure of neuroinflammation
[58,59]. Our data suggest that amyloid is strongly and
causally associated with tau pathology but not with synaptic
dysfunction or neuroinflammation. Instead, we found that
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cating that synaptic dysfunction and neuroinflammation are
consequences of tau-pathological processes. Interestingly,
similar observations have been made and are in line with our
findings. For example, inmultiple transgenicmodels, amyloid
pathology results invery little neuronal damage, synaptic loss,
or indeed neuroinflammation, and where such pathological
consequences do exist, they are abolished in the context of
ablation of tau [60–62]. Although these findings are
necessarily preliminary, they suggest that proteomic and
perhaps other high-dimensionality molecular biomarker
studies might also contribute to an understanding of patholog-
ical processes in disease.
We acknowledge that the sample origin is a limitation of
this study. Given that both the discovery and replication
samples are taken from the same meta-sample collection,
it is not an independent validation in the traditional sense.
However, because the EMIF-AD MBD study is a multi-
centre study and collected samples from 11 centers across
Europe, the meta-collection reflects the challenges faced in
the real world of multisite and multinational clinical
studies. Therefore, the replication obtained in this study
in such a collection of samples has a higher probability
of effective utility in practice.
In conclusion, our results strongly suggest that testing
high-dimensional plasma protein levels is a useful and repro-
ducible approach to measure central nervous system amy-
loid deposition. This can be potentially applied as a
prescreen to preselect patients for further selection proced-
ures for clinical trials, thus reducing the cost incurred to clin-
ical trials by screen failure. Furthermore, we confirmed the
causal relationship between amyloid and tau pathology
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1. Systematic review: We reviewed the literature using
PubMed sources, meeting abstracts, and presenta-
tions. Plasma proteins have been widely studied as
candidate biomarkers to predict brain amyloid depo-
sition, but most such studies are targeted to specific
proteins or are biased toward high abundant proteins.
Furthermore, the mechanism of AD pathology is still
disputed, with serial trials failure provoking some to
question the amyloid cascade hypothesis.
2. Interpretation: Our findings showed that testing
plasma proteins using the high-dimensionality SO-
MAscan assay could be a useful and reproducible
approach for indicating brain amyloid deposition as
well as tau pathology. Furthermore, we confirmed the
crucial role of amyloid pathology in AD process with
a novel use of Mendelian randomization.
3. Future directions: Although it looks promising that a
blood test could be used as a tool to preselect individ-
uals for further clinical trials, the plasma biomarkers
identified from this study need to be further validated
in a larger and independent cohort.
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